Please login to the form below

Not currently logged in
Email:
Password:

Pfizer strengthens board of directors

Ronald Blaylock brings financial and business leadership expertise

Pfizer Ronald BlaylockPfizer has bolstered its board of directors with the appointment of Ronald Blaylock, who joins with immediate effect.

Blaylock currently serves as managing partner of private equity firm GenNx360 Capital Partners, which he founded in 2006.

Prior to this, he founded investment banking firm Blaylock & Company in 1993, subsequently serving as chairman and chief executive officer.

He brings further senior management experience from Paine Webber and CitiGroup, and currently serves on the boards of CarMax, Radio One, WR Berkley and Syncreon.

Ian Read, Pfizer's chairman and chief executive officer, said: “We are pleased to welcome Ron Blaylock to Pfizer's board of directors.

“He brings business, financial and leadership expertise, which will be an asset to Pfizer's diverse board and to our company. The addition of Ron to our board helps to ensure that Pfizer continues to benefit from a breadth and variety of experience.”

28th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics